TG Therapeutics, Inc. (TGTX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Morrisville, NY, United States. Der aktuelle CEO ist Michael S. Weiss.
TGTX hat IPO-Datum 2010-05-03, 352 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $5.52B.
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel treatments targeting B-cell malignancies and autoimmune diseases. The company's lead products include Ublituximab, a monoclonal antibody for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis, and Umbralisib, an oral PI3K-delta and CK1-epsilon inhibitor for various lymphomas and leukemia. The pipeline also includes clinical and preclinical candidates such as Cosibelimab (a PD-L1 inhibitor), TG-1701 (a BTK inhibitor), TG-1801 (a bispecific CD47/CD19 antibody), and programs targeting BET, IRAK-4, and GITR. Founded in 1993 and headquartered in New York, TG Therapeutics maintains strategic collaborations and partnerships with leading global pharmaceutical and biotechnology organizations to advance its therapeutic development programs.
